Every year, pharmaceutical executives sit in board rooms and learn that a product generating hundreds of millions of dollars in […]

The Hatch-Waxman Act was never designed to be a gift to branded pharmaceutical companies. Congress passed the Drug Price Competition

This is the arbitrage opportunity. The pharmaceutical secondary market — distressed assets, out-licensed compounds, abandoned pipelines, post-patent small molecules —

The instinct, when a primary patent approaches expiration, is to treat it as a loss event. Revenue projections get marked

The pharmaceutical industry operates on a high-risk model where the cost of a single drug approval ranges from $1 billion

Pharmaceutical manufacturers face a revenue contraction of 62% from their top-selling assets by 2030.1 Blockbuster drugs representing $236 billion in

How to use market automation and drug patent intelligence to build pipeline before generic entry kills your best customers’ budgets

Pharmaceutical companies lose between $200 billion and $400 billion in annual revenue to patent expirations between 2025 and 2030. This

The Statute That Rewired the Drug Industry In September 1984, President Reagan signed two pieces of legislation that had been